150 filings
Page 2 of 8
6-K
eeiufbch9o74d8uqf8i
9 Nov 22
Current report (foreign)
7:03am
6-K
ogwsm0b3
21 Sep 22
Current report (foreign)
4:16pm
6-K
vimpv
11 Aug 22
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
7:33am
6-K
peqw78o845g 6ou
4 Aug 22
Current report (foreign)
7:18am
6-K
lzj60kkzw9g5yu1a
30 Jun 22
Current report (foreign)
4:32pm
6-K
7buzw9l29rzlx4q
1 Jun 22
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
7:05am
6-K
a6dudivl
5 May 22
Current report (foreign)
12:00am
6-K
xs3b11 y8lwiz
13 Apr 22
Current report (foreign)
8:02am
6-K
o78u7
13 Apr 22
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
7:09am
6-K
k6c75li
24 Feb 22
Current report (foreign)
7:39am
6-K
ftxu89eyzaqyw9c17us
11 Feb 22
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
7:39am
6-K
xlh76imdw wbfaciybmx
4 Jan 22
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
7:12am
6-K
81m 89fdul
30 Dec 21
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
7:19am
6-K
y81j1a
16 Dec 21
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A mediated Retinitis Pigmentosa
7:23am
6-K
ofhp9zw02x4oy4d zqk1
18 Nov 21
ProQR Announces Highlights from Analyst Event
4:25pm
6-K
6pak1qxire1r
18 Nov 21
Current report (foreign)
11:46am
6-K
dzugj j00l1g1v
4 Nov 21
Current report (foreign)
7:30am
6-K
i8kfuhcn utqivdhrk
4 Oct 21
ProQR Appoints Theresa Heggie as Chief Commercial Officer
8:21am
6-K
c2b4gcg1
9 Sep 21
Current report (foreign)
8:01am
6-K
094pw5le6fm4 gnu38f
8 Sep 21
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
4:10pm